Patents by Inventor David Philip Lane
David Philip Lane has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220372125Abstract: The present disclosure relates to an antigen specific binding domain which binds to RON (Macrophage Stimulating Protein Receptor or Recepteur d'Origine Nantais). The disclosure also extends to chimeric antigen receptors (and a cell expressing the same), antibody molecules (including full length antibodies and fragments thereof, as well as antibody conjugates) containing the antigen binding domains disclosed herein. Also disclosed herein are pharmaceutical compositions comprising the cells, antibody molecules as disclosed herein. The present disclosure also refers to the use of the antigen binding domains, the chimeric antigen receptors, the antibody molecules and the pharmaceutical compositions disclosed herein in therapy, more particularly in treating cancer. Also disclosed herein are radiolabelled antibody conjugates comprising the antigen binding domains as disclosed, and their use in methods of treatment or diagnosis.Type: ApplicationFiled: October 2, 2020Publication date: November 24, 2022Inventors: Xin Yu Koh, David Philip Lane
-
Patent number: 9994644Abstract: Antibodies specifically binding an epitope comprised in the ?-chain of c-Met, modifications, compositions and uses thereof are disclosed herein.Type: GrantFiled: March 28, 2014Date of Patent: June 12, 2018Assignee: Agency for Science, Technology and ResearchInventors: Shuxian Julin Wong, David Philip Lane
-
Patent number: 9365508Abstract: The invention provides compounds according to formula (I): (wherein X, Y, Z1 R1, R2, R3, Ar and Ar? are as defined herein), and physiologically acceptable salts, solvates, esters or amides thereof, pharmaceutical compositions comprising these compounds and the compounds for use in medicine, for example for the treatment or prophylaxis of diseases involving cell proliferation, such as cancer, and for the treatment or prophylaxis of other diseases.Type: GrantFiled: June 9, 2010Date of Patent: June 14, 2016Assignees: University Court of the University of St Andrews, University Court of the University of DundeeInventors: Sonia Lain, Nicholas James Westwood, David Philip Lane
-
Publication number: 20160083479Abstract: Antibodies specifically binding an epitope comprised in the ?-chain of c-Met, modifications, compositions and uses thereof are disclosed herein.Type: ApplicationFiled: March 28, 2014Publication date: March 24, 2016Inventors: Shuxian Julin Wong, David Philip Lane
-
Publication number: 20160046672Abstract: The present invention relates to cross-linked peptides that are associated with human eIF4G and bind to eIF4E, uses thereof and pharmaceutical compositions comprising the peptides.Type: ApplicationFiled: February 28, 2014Publication date: February 18, 2016Inventors: Christopher John Brown, David Philip Lane, Soo Tng Quah, Dilraj Lama, Chandra Shekhar Verma
-
Publication number: 20150276755Abstract: The present disclosure provides a method of determining resistance of a biological molecule to inhibition of its interaction with a target molecule by an inhibitor of the biological molecule, the method comprising the steps of: a) co-compartmentalizing a gene encoding the biological molecule with the target molecule, or a gene encoding the biological molecule with a gene encoding the target molecule into an aqueous droplet disposed within a water-in-oil emulsion, and b) assaying for a complex comprising the biological molecule and the target molecule upon expression of the gene encoding the biological molecule and the gene encoding the target molecule, wherein detection of the complex in the presence of the inhibitor indicates that the biological molecule is resistant to inhibition of its interaction with the target molecule by the inhibitor. Also provided are mutated HDM2 ubiquitin ligase polypeptides exhibiting resistance to Nutlin inhibition of p53 binding.Type: ApplicationFiled: October 25, 2013Publication date: October 1, 2015Inventors: Farid Ghadessy, Chandra Shekhar Verma, David Philip Lane, Jia Wei Siau, Thomas Leonard Joseph, Adelene Yen Ling Sim
-
Publication number: 20120149778Abstract: The invention provides compounds according to formula (I): (wherein X, Y, Z1 R1, R2, R3, Ar and Ar? are as defined herein), and physiologically acceptable salts, solvates, esters or amides thereof, pharmaceutical compositions comprising these compounds and the compounds for use in medicine, for example for the treatment or prophylaxis of diseases involving cell proliferation, such as cancer, and for the treatment or prophylaxis of other diseases.Type: ApplicationFiled: June 9, 2010Publication date: June 14, 2012Inventors: Sonia Lain, Nicholas James Westwood, David Philip Lane
-
Publication number: 20080249025Abstract: p21WAF1 interacts with cyclin D1 and Cdk4. Peptide fragments of p21 inhibit the interaction and/or affect Cdk4 activity. The peptides, derivative peptides and non-peptidyl mimetics thereof are useful in affecting activity of Cdk4, such as RB phosphorylation and cellular proliferation, indicative of therapeutic usefullness in treatment of tumors and other hyperproliferative disorders. Assay and screening methods allow identification of such modulators, especially inhibitors, of Cdk4 activity.Type: ApplicationFiled: June 4, 2008Publication date: October 9, 2008Applicant: Cyclacel LimitedInventors: Kathryn Lindsay Ball, David PHilip Lane
-
Patent number: 7141541Abstract: We claim a therapeutic method of inducing programmed cell death comprising administering to a recipient a peptide of 10–25 amino acids, comprising the sequence: (KR)xxYxxx(F/Q)L(L/M) wherein x is any amino acid.Type: GrantFiled: June 21, 2000Date of Patent: November 28, 2006Assignee: University Court of the University of DundeeInventors: Christopher Gregory Proud, Terrence Patrick Herbert, David Philip Lane, Robin Fahraeus
-
Patent number: 7083983Abstract: The present invention relates to compounds capable of binding to the oncogene protein MDM2, processes for the preparation of such compounds, pharmaceutical preparations comprising such compounds, and uses of said compounds, e.g. in the therapeutic (including prophylactic) treatment of an animal or especially of the human body. The present further relates to methods of and compounds for inhibiting the growth of tumor cells which comprise the wild type p53 suppressor by interfering with the interaction between human p53 and human MDM2.Type: GrantFiled: July 4, 1997Date of Patent: August 1, 2006Assignee: Cancer Research Campaign Technology LimitedInventors: David Philip Lane, Volker Böttger, Angelika Böttger, Steven Michael Picksley, Heinz-Kurt Hochkeppel, Carlos Garcia-Echeverria, Patrick Chène, Pascal Furet
-
Patent number: 6962792Abstract: p21WAF1 interacts with cyclin D1 and Cdk4. Peptide fragments of p21 inhibit the interaction and/or affect Cdk4 activity. The peptides, derivative peptides and non-peptidyl mimetics thereof are useful in affecting activity of Cdk4, such as RB phosphorylation, and cellular proliferation, indicative of therapeutic usefulness in treatment of tumours and other hyperproliferative disorders. Assay and screening methods allow identification of such modulators, especially inhibitors, of Cdk4 activity.Type: GrantFiled: May 8, 1997Date of Patent: November 8, 2005Assignee: Cyclacel LimitedInventors: Kathryn Lindsay Ball, David Philip Lane
-
Publication number: 20040214765Abstract: p21WAF1 interacts with cyclin D1 and Cdk4. Peptide fragments of p21 inhibit the interaction and/or affect Cdk4 activity. The peptides, derivative peptides and non-peptidyl mimetics thereof are useful in affecting activity of Cdk4, such as RB phosphorylation, and cellular proliferation, indicative of therapeutic usefulness in treatment of tumours and other hyperproliferative disorders. Assay and screening methods allow identification of such modulators, especially inhibitors, of Cdk4 activity.Type: ApplicationFiled: August 22, 2003Publication date: October 28, 2004Inventors: Kathryn Lindsay Ball, David Philip Lane
-
Publication number: 20040146971Abstract: The present invention relates to a protein which is induced by p53 and which promotes apoptosis. The present invention also relates to the gene encoding the protein as well as vectors and the like comprising the gene and also uses the gene/protein associated with promoting apoptosis.Type: ApplicationFiled: February 24, 2004Publication date: July 29, 2004Inventors: David Philip Lane, Jean-Christophe Bourdon, Jochen Renzing
-
Publication number: 20040029791Abstract: The present invention identifies substances having the property of binding to cyclin dependent kinase (cdk) comprising: (i) a peptide including amino acid residues 84 to 103 of full length p16 protein, or an active portion or derivative thereof; or (ii) a functional mimetic of the fragment. active portion or derivative; the substance excludes full length p16. p15. p18 and p19 proteins. These substances are useful in tumour suppression by inhibiting the phosphorylation of Rb protein. Also described herein is the resolution of the amino acid motifs responsible for binding cdks, an FLD motif. corresponding to amino acid residues 90 to 92 of full length p16 protein. and an LVVL motif, corresponding to amino acid residues 94 to 97 of full length p16 protein. The substances disclosed herein can be used in the treatment of hyperproliferative disorders and to screen and design molecules having the similar properties.Type: ApplicationFiled: November 1, 2002Publication date: February 12, 2004Applicant: Cyclacel LimitedInventors: Robin Fahraeus, David Philip Lane
-
Patent number: 6569833Abstract: The present disclosure identifies substances having the property of binding to cyclin dependent kinase (cdk) comprising: (i) a peptide including amino acid residue 84 to 103 of full length p16 protein, or an active portion or derivative thereof; or (ii) a functional mimetic of the fragment, active portion or derivative; the substance excludes full length p16, p15, p18 and p19 proteins. These substances are useful in tumor suppression by inhibiting the phosphorylation of Rb protein. Also described herein is the resolution of the amino acid motifs responsible for binding cdks, an FLD motif, corresponding to amino acid residues 90 to 92 of full length p16 protein, and an LVVL motif, corresponding to amino acid residues 94 to 97 of full length p16 protein. The substances disclosed herein can be used in the treatment of hyperproliferative disorders and to screen and design molecules having the similar properties.Type: GrantFiled: April 7, 1999Date of Patent: May 27, 2003Assignee: Cyclacel LimitedInventors: Robin Fahraeus, David Philip Lane
-
Patent number: 6242201Abstract: Substances are disclosed which have the property of binding to PCNA, the substances comprising (i) a fragment of the p21WAF1 protein including residues 141 to 160 of the p21WAF1 amino acid sequence, or an active portion or derivative thereof; or (ii) functional mimetics of these protein fragments. In particular, the PCNA binding activity is shown to lie within the sequence motif OTSMTDFY, with the residues shown in bold being critical for PCNA binding, with those underlined being important. These substances are useful in the treatments of disorders in which PCNA is implicated, e.g. hyperproliferative disorders such as cancer and psoriasis, the substances binding to PCNA to inactivate it or functionally deplete its level. Also disclosed is the use of a yeast two hybrid screening technique for screening candidate peptides for binding to PCNA.Type: GrantFiled: August 22, 1997Date of Patent: June 5, 2001Assignee: Cyclacel LimitedInventors: David Philip Lane, Lynne Suzanne Cox, Emma Warbrick, David Moore Glover
-
Patent number: 6153391Abstract: A method for interfering with the binding between p53 and MDM2 or a protein having a p53 binding site analogous to that of MDM2, which method comprises administering a effective amount of a compound, selected from the group consisting of a peptide having up to twenty eight amino acids which is able to disrupt or prevent binding between p53 and MDM2, or a functional peptide analogue thereof.Compounds for use in the method, methods for detecting such compounds and their application in the diagnosis and treatment of tumors is also described and claimed.Type: GrantFiled: March 5, 1998Date of Patent: November 28, 2000Assignee: University of DundeeInventors: Steven Michael Picksley, David Philip Lane
-
Patent number: 6140058Abstract: A class of mutant forms of p53 protein, such as His273 and Lys285, which are defective in conversion from the latent to the activated state by casein kinase II, but with the ability to be activated for specific DNA binding by the action of ligands such as monoclonal antibody PAb421 and heat shock protein DnaK. Activation of these mutants, which are found at high levels in certain types of tumour, can potentially lead to selective growth arrest and induction of apoptosis in the tumor cells. p53 can be constitutively activated also by deletion of the C-terminal 30 amino acids. p53 activated in this way, or by ligand binding, can be administered for the purposes of tumour or cell growth suppression.Type: GrantFiled: July 24, 1995Date of Patent: October 31, 2000Assignee: Newburn EllisInventors: David Philip Lane, Theodore Robert Hupp
-
Patent number: 6020149Abstract: A method for determining the anti-microbial activity of a putative anti-microbial agent includes combining a microbially required nucleotide phosphatase, a nucleoside phosphate and the substance to be tested, and assessing the extent of degradation of the nucleoside phosphate in the presence and absence of the substance. The method thus allows the determination of the extent of inhibition of the nucleotide phosphatase by the substance. Preferably the method determines the degree of inhibition of an RNA helicase such as DbpA, which acts selectively on prokaryotic ribosomal RNA. Suitable DbpA inhibitors as well as genetic material encoding for an active form of DbpA are used.Type: GrantFiled: September 15, 1997Date of Patent: February 1, 2000Assignee: The University Court of the University of DundeeInventors: Frances Victoria Fuller-Pace, David Philip Lane
-
Patent number: 5770377Abstract: A method for interfering with the binding between p53 and MDM2 or a protein having a p53 binding site analogous to that of MDM2, which method comprises administering a effective amount of a compound, selected from the group consisting of a peptide having up to twenty eight amino acids which is able to disrupt or prevent binding between p53 and MDM2, or a functional peptide analogue thereof.Compounds for use in the method, methods for detecting such compounds and their application in the diagnosis and treatment of tumours is also described and claimed.Type: GrantFiled: April 19, 1995Date of Patent: June 23, 1998Assignee: University of DundeeInventors: Steven Michael Picksley, David Philip Lane